Janus Henderson Group
CYTK icon

Janus Henderson Group’s Cytokinetics CYTK Stock Holding History

Janus Henderson Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6M Buy
282,121
+25,909
+10% +$1.65M 0.01% 620
2025
Q4 		$16.3M Buy
256,212
+206,648
+417% +$12.9M 0.01% 647
2025
Q3 		$2.73M Hold
49,564
– – ﹤0.01% 1185
2025
Q2 		$1.64M Sell
49,564
-1,007,582
-95% -$35M ﹤0.01% 1382
2025
Q1 		$45.7M Buy
1,057,146
+32,729
+3% +$1.5M 0.03% 396
2024
Q4 		$48.2M Sell
1,024,417
-119,413
-10% -$6.2M 0.02% 397
2024
Q3 		$60.4M Buy
1,143,830
+167,501
+17% +$9.34M 0.03% 346
2024
Q2 		$52.9M Buy
976,329
+178,957
+22% +$10.8M 0.03% 368
2024
Q1 		$55.9M Sell
797,372
-1,771,033
-69% -$137M 0.03% 370
2023
Q4 		$214M Buy
2,568,405
+75,079
+3% +$2.72M 0.13% 173
2023
Q3 		$73.5M Buy
2,493,326
+397,627
+19% +$13.2M 0.05% 286
2023
Q2 		$68.4M Buy
2,095,699
+522,055
+33% +$19.3M 0.04% 329
2023
Q1 		$55.4M Buy
1,573,644
+1,399,714
+805% +$57.1M 0.04% 361
2022
Q4 		$7.97M Buy
173,930
+158,967
+1,062% +$6.84M 0.01% 766
2022
Q3 		$725K Buy
14,963
+21
+0.1% +$1.01K ﹤0.01% 1430
2022
Q2 		$587K Sell
14,942
-6
-0% -$242 ﹤0.01% 1669
2022
Q1 		$550K Buy
14,948
+4
+0% +$142 ﹤0.01% 1850
2021
Q4 		$682K Buy
14,944
+7,528
+102% +$290K ﹤0.01% 1694
2021
Q3 		$265K Buy
+7,416
New +$218K ﹤0.01% 1956
2017
Q4 		– Sell
-2,778,605
Closed -$40.3M – 1313
2017
Q3 		$40.3M Buy
2,778,605
+93,675
+3% +$1.28M 0.03% 573
2017
Q2 		$32.5M Buy
+2,684,930
New +$37.3M 0.02% 630

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Janus Henderson Group's CYTK Position: Q1 2026 in Review

Janus Henderson Group increased its Cytokinetics (CYTK) stake by 10% in Q1 2026, buying an estimated $1.65M and bringing the position to 282,121 shares worth $18.6M. The position accounts for 0.01% of the portfolio, ranked #620.

Janus Henderson Group first reported a position in CYTK in Q2 2017 and has held it in 21 quarters since. The position peaked at $214M in Q4 2023. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Janus Henderson Group held 282,121 shares of Cytokinetics worth $18.6M as of Q1 2026.
  • Janus Henderson Group bought 25,909 Cytokinetics shares in Q1 2026, an estimated $1.65M.
  • Cytokinetics made up 0.01% of Janus Henderson Group's portfolio in Q1 2026, its #620 holding.
  • Janus Henderson Group first reported a position in Cytokinetics in Q2 2017 and has held it in 21 quarters since.
  • Janus Henderson Group's Cytokinetics position peaked at $214M in Q4 2023.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.